Sotera Health (Nasdaq:SHC) - Aandelenkoers, Nieuws & Analyse

SHC Overzicht aandelen

Sotera Health Company houdt zich bezig met sterilisatie, laboratoriumtests en adviesdiensten in de Verenigde Staten en internationaal.

Over het bedrijf

SHC fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Verhandeld tegen 35.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 48.18% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Rentebetalingen worden niet goed gedekt door de winsten

Grote eenmalige posten die de financiële resultaten beïnvloeden

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth

Key Takeaways Sotera Health's strategic pricing and capacity expansion reflect confidence in maintaining or growing future revenue and net margins, despite economic pressures. Initiatives for operational efficiency, such as positive free cash flow and improved debt refinancing, forecast a strong financial health and flexibility for future growth or shareholder returns.

View narrative

US$16.36

3.4% undervalued

5.62%

Revenue growth p.a.

6 days ago

Sotera Health Company Concurrenten

Syneos Health

NasdaqGS:SYNH

US$4.5b

Stevanato Group

NYSE:STVN

US$5.3b

Charles River Laboratories International

NYSE:CRL

US$9.3b

Bruker

NasdaqGS:BRKR

US$9.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sotera Health
Historische aandelenkoersen
Huidige aandelenkoers	US$15.80
52 Week Hoogtepunt	US$17.44
52 Week Laag	US$10.71
Bèta	2.08
11 maand verandering	0%
3 maanden verandering	7.48%
1 Jaar Verandering	18.00%
33 jaar verandering	-42.08%
5 jaar verandering	n/a
Verandering sinds IPO	-37.05%

Recent nieuws en updates

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sep 02

Recent updates

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sep 02

Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Jun 25

Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 30

The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Mar 21

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Mar 01

McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount

Feb 08

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Feb 06

Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Dec 28

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

Dec 11

An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sep 10

Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jun 05

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Feb 13

Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Nov 24

Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit

Sep 19

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Sep 08

Sotera Health GAAP EPS of $0.11 misses by $0.05, revenue of $266.64M beats by $10.34M

Aug 04

Rendement voor aandeelhouders

	SHC	US Life Sciences	US Markt
7D	-0.2%	2.1%	-1.9%
1Y	18.0%	18.5%	30.4%

Rendement versus industrie: SHC kwam overeen met de US Life Sciences industrie, die het afgelopen jaar een rendement opleverde van 18.5 %.

Rendement versus markt: SHC presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.4 % opleverde.

Prijsvolatiliteit

Is SHC's price volatile compared to industry and market?
SHC volatility
SHC Average Weekly Movement	5.2%
Life Sciences Industry Average Movement	7.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: SHC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van SHC is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	3,000	Michael Petras	soterahealth.com

Sotera Health Company houdt zich bezig met sterilisatie, laboratoriumtests en adviesdiensten in de Verenigde Staten en internationaal. Het bedrijf is actief via drie segmenten: Sterigenics, Nordion en Nelson Labs. Het bedrijf levert bedrijfskritische end-to-end sterilisatiediensten, waaronder gamma- en elektronenbundelbestraling en ethyleenoxideverwerking, en ontwerpt, installeert en onderhoudt gammabestralingssystemen.

Sotera Health Company Samenvatting

Hoe verhouden de winst en inkomsten van Sotera Health zich tot de beurswaarde?
SHC fundamentele statistieken
Marktkapitalisatie	US$4.49b
Inkomsten(TTM)	US$39.94m
Inkomsten(TTM)	US$1.10b

112.0x

Koers/Winstverhouding

4.1x

P/S-verhouding

Is SHC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SHC resultatenrekening (TTM)
Inkomsten	US$1.10b
Kosten van inkomsten	US$492.21m
Brutowinst	US$605.97m
Overige uitgaven	US$566.04m
Inkomsten	US$39.94m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 05, 2024

Winst per aandeel (EPS)	0.14
Brutomarge	55.18%
Nettowinstmarge	3.64%
Schuld/Eigen Vermogen Verhouding	526.2%

Hoe presteerde SHC op de lange termijn?

Bekijk historische prestaties en vergelijking

SHC Overzicht aandelen

Beloningen

Risicoanalyse

Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth

Sotera Health Company Concurrenten

NasdaqGS:SYNH

US$4.5b

NYSE:STVN

US$5.3b

NYSE:CRL

US$9.3b

NasdaqGS:BRKR

US$9.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Sotera Health Company to Report Q3, 2024 Results on Nov 05, 2024

Sotera Health Company has completed a Follow-on Equity Offering in the amount of $375.75 million.

Sotera Health Company has filed a Follow-on Equity Offering.

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Consensus EPS estimates fall by 12%

Recent updates

Sotera Health Company to Report Q3, 2024 Results on Nov 05, 2024

Sotera Health Company has completed a Follow-on Equity Offering in the amount of $375.75 million.

Sotera Health Company has filed a Follow-on Equity Offering.

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Consensus EPS estimates fall by 12%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$16.36

Sotera Health Company Reaffirms Earnings Guidance for the 2024

Sotera Health Appoints Christopher Simon to the Board of Directors

Sotera Health Company to Report Q2, 2024 Results on Aug 05, 2024

Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

Sotera Health Company Reports Impairment of Long-Lived Assets for the Three Months Ended March 31, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sotera Health Company to Report Q1, 2024 Results on May 02, 2024

The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 19%

Sotera Health Company has completed a Follow-on Equity Offering in the amount of $368.75 million.

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Sotera Health Company Provides Revenue Guidance for the Full-Year 2024

Sotera Health Company has filed a Follow-on Equity Offering.

Full year 2023 earnings: EPS misses analyst expectations

Sotera Health Company to Report Q4, 2023 Results on Feb 27, 2024

McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Now 21% undervalued

Now 20% undervalued

Sotera Health Company Provides Preliminary Revenue Guidance for the Year 2023

Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

Sotera Health Appoints Karen Flynn to Board of Directors

Price target decreased by 14% to US$17.17

Sotera Health Company Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Sotera Health Company to Report Q3, 2023 Results on Nov 01, 2023

An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sotera Health Company Revises Updated Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Sotera Health Company Appoints Jon Lyons as Chief Financial Officer

Sotera Health Company Appoints Jon Lyons as Chief Financial Officer

Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Sotera Health Company Re-Affirms Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Now 20% undervalued after recent price drop

Now 20% undervalued

Full year 2022 earnings: EPS misses analyst expectations

Sotera Health Company to Report Q4, 2022 Results on Feb 28, 2023

Sotera Health Company Reaffirms Earnings Guidance for the Year Ended December 31, 2022

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Sotera Health Company

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Sotera Health Company

Consensus forecasts updated

Investor sentiment improved over the past week

Consensus forecasts updated

Price target increased to US$12.50

Sotera Health Company Announces Settlement of Ethylene Oxide Litigation in Illinois

Investor sentiment deteriorated over the past week

Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher